Literature DB >> 12117035

Survey of patients' views of domiciliary nebuliser treatment for chronic lung disease.

S K Barta1, A Crawford, C Michael Roberts.   

Abstract

There is some controversy amongst respiratory physicians over the value of domiciliary nebuliser use for chronic lung conditions. Most recommendations for assessment of suitability for this form of treatment rely upon response to lung function tests and reported improvements in exercise ability. Relatively little emphasis has been placed upon the patient view of this therapy. This survey examined the subjective views of patients receiving domiciliary nebulisers regarding this treatment. A postal questionnaire was sent to 82 patients using home nebuliser treatment provided by the respiratory clinic at Whipps Cross University Hospital, London. It consisted of 29 structured questions covering topics of well-being and symptom control, self-confidence, dependency, time and technical issues, as well as side effects and compliance. Most patients surveyed had chronic obstructive lung disease. For almost all sections of the questionnaire patients reported overwhelmingly that the benefits of using a nebuliser outweighed potential disadvantages. The main perceived advantages werethe ability for patients themselves to control symptoms and to be less dependent on General Practitioners, hospitals and carers. Compliance was generally excellent, and the reported side effects were minor and relatively infrequent. The results strongly support the view that nebulisers are helpful in managing chronic lung disease in the community with benefit to patient well-being and potential health cost savings.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117035     DOI: 10.1053/rmed.2001.1292

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  14 in total

1.  Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus.

Authors:  Robert A Wise; Russell A Acevedo; Antonio R Anzueto; Nicola A Hanania; Fernando J Martinez; Jill A Ohar; Donald P Tashkin
Journal:  Chronic Obstr Pulm Dis       Date:  2016-11-15

2.  Evaluation of patient-reported outcomes and quality of life with the I-neb AAD system in patients with chronic obstructive pulmonary disease.

Authors:  Nicola Goodman; Mike Morgan; Kurt Nikander; Sarah Hinch; Steven Coughlin
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

Review 3.  Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend.

Authors:  Christopher M Blanchette; Nicholas J Gross; Pablo Altman
Journal:  Am Health Drug Benefits       Date:  2014-04

Review 4.  Optimising Inhaled Pharmacotherapy for Elderly Patients with Chronic Obstructive Pulmonary Disease: The Importance of Delivery Devices.

Authors:  Federico Lavorini; Claudia Mannini; Elisa Chellini; Giovanni A Fontana
Journal:  Drugs Aging       Date:  2016-07       Impact factor: 3.923

5.  Assistance of family carers for patients with COPD using nebulisers at home: a qualitative study.

Authors:  Bothaina Alhaddad; Kevin Mg Taylor; Tricia Robertson; Geoffrey Watman; Felicity J Smith
Journal:  Eur J Hosp Pharm       Date:  2015-11-02

Review 6.  A review of nebulized drug delivery in COPD.

Authors:  Donald P Tashkin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-10-18

Review 7.  Medication adherence issues in patients treated for COPD.

Authors:  Ruben D Restrepo; Melissa T Alvarez; Leonard D Wittnebel; Helen Sorenson; Richard Wettstein; David L Vines; Jennifer Sikkema-Ortiz; Donna D Gardner; Robert L Wilkins
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 8.  Exacerbation rate, health status and mortality in COPD--a review of potential interventions.

Authors:  Terence A R Seemungal; John R Hurst; Jadwiga A Wedzicha
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-06-11

9.  Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease.

Authors:  Brian R Leaker; Peter J Barnes; C Richard Jones; Ahmet Tutuncu; Dave Singh
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

10.  Evaluation of patient preference and willingness to pay for attributes of maintenance medication for chronic obstructive pulmonary disease (COPD).

Authors:  Ariane K Kawata; Leah Kleinman; Gale Harding; Sulabha Ramachandran
Journal:  Patient       Date:  2014       Impact factor: 3.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.